BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marcotte R, Sayad A, Brown KR, Sanchez-Garcia F, Reimand J, Haider M, Virtanen C, Bradner JE, Bader GD, Mills GB, Pe'er D, Moffat J, Neel BG. Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell 2016;164:293-309. [PMID: 26771497 DOI: 10.1016/j.cell.2015.11.062] [Cited by in Crossref: 250] [Cited by in F6Publishing: 228] [Article Influence: 41.7] [Reference Citation Analysis]
Number Citing Articles
1 Voutsadakis IA. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors. Gene 2022;847:146881. [PMID: 36100115 DOI: 10.1016/j.gene.2022.146881] [Reference Citation Analysis]
2 Kim C, Wang X, Wang S, Li P, Zi Z, Ding Q, Jang S, Kim J, Luo Y, Huffman KE, Cai L, Liang H, Minna JD, Yu Y. Induced Degradation of Lineage-specific Oncoproteins Drives the Selective PARP1 Inhibitor Toxicity in Small Cell Lung Cancer.. [DOI: 10.1101/2022.11.02.514072] [Reference Citation Analysis]
3 van Leeuwen JE, Ba-Alawi W, Branchard E, Cruickshank J, Schormann W, Longo J, Silvester J, Gross PL, Andrews DW, Cescon DW, Haibe-Kains B, Penn LZ, Gendoo DMA. Computational pharmacogenomic screen identifies drugs that potentiate the anti-breast cancer activity of statins. Nat Commun 2022;13:6323. [PMID: 36280687 DOI: 10.1038/s41467-022-33144-9] [Reference Citation Analysis]
4 Voutsadakis IA. Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential. Medicina (Kaunas) 2022;58:1498. [PMID: 36295658 DOI: 10.3390/medicina58101498] [Reference Citation Analysis]
5 Deng N, Minoche A, Harvey K, Li M, Winkler J, Goga A, Swarbrick A. Deep whole genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models. Breast Cancer Res 2022;24. [DOI: 10.1186/s13058-022-01540-0] [Reference Citation Analysis]
6 Lauko A, Volovetz J, Turaga SM, Bayik D, Silver DJ, Mitchell K, Mulkearns-Hubert EE, Watson DC, Desai K, Midha M, Hao J, McCortney K, Steffens A, Naik U, Ahluwalia MS, Bao S, Horbinski C, Yu JS, Lathia JD. SerpinB3 drives cancer stem cell survival in glioblastoma. Cell Rep 2022;40:111348. [PMID: 36103817 DOI: 10.1016/j.celrep.2022.111348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Soria-Bretones I, Thu KL, Silvester J, Cruickshank J, El Ghamrasni S, Ba-Alawi W, Fletcher GC, Kiarash R, Elliott MJ, Chalmers JJ, Elia AC, Cheng A, Rose AAN, Bray MR, Haibe-Kains B, Mak TW, Cescon DW. The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor-resistant ER+ breast cancer with mitotic aberrations. Sci Adv 2022;8:eabq4293. [PMID: 36070391 DOI: 10.1126/sciadv.abq4293] [Reference Citation Analysis]
8 van der Noord VE, van de Water B, Le Dévédec SE. Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery. Cancers 2022;14:4353. [DOI: 10.3390/cancers14184353] [Reference Citation Analysis]
9 Chen H, Liu Z, Zheng L, Wang R, Shi L. BET inhibitors: an updated patent review (2018-2021). Expert Opin Ther Pat 2022. [PMID: 35982031 DOI: 10.1080/13543776.2022.2115354] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Temena MA, Acar A. Increased TRIM31 gene expression is positively correlated with SARS-CoV-2 associated genes TMPRSS2 and TMPRSS4 in gastrointestinal cancers. Sci Rep 2022;12:11763. [PMID: 35970857 DOI: 10.1038/s41598-022-15911-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Lee S, Osmanbeyoglu HU. Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas. Breast Cancer Res 2022;24:54. [PMID: 35906698 DOI: 10.1186/s13058-022-01550-y] [Reference Citation Analysis]
12 Tsai YS, Chareddy YS, Price BA, Parker JS, Pecot CV. An integrated model for predicting KRAS dependency.. [DOI: 10.1101/2022.07.07.499238] [Reference Citation Analysis]
13 Markowska M, Budzinska MA, Coenen-stass A, Kang S, Kizling E, Kolmus K, Koras K, Staub E, Szczurek E. SLIDE-VIP: a comprehensive, cell line- and patient-based framework for synthetic lethality prediction in DNA damage repair, chromatin remodeling and cell cycle.. [DOI: 10.1101/2022.07.07.499118] [Reference Citation Analysis]
14 Zhang K, Gao L, Wang J, Chu X, Zhang Z, Zhang Y, Fang F, Tao Y, Li X, Tian Y, Li Z, Sang X, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Pan J, Hu S. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. Pathol Oncol Res 2022;28:1610447. [DOI: 10.3389/pore.2022.1610447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sun R, Zhu Y, Sayad A, Ge W, Luna A, Liang S, Segura LT, Rajapakse VN, Yu C, Zhang H, Fang J, Wu F, Xie H, Saez-rodriguez J, Ying H, Reinhold WC, Sander C, Pommier Y, Neel BG, Guo T, Aebersold R. Proteomic Dynamics of Breast Cancers Identifies Potential Therapeutic Protein Targets.. [DOI: 10.1101/2022.06.03.494776] [Reference Citation Analysis]
16 Cheng GJ, Leung EY, Singleton DC. In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00084] [Reference Citation Analysis]
17 Wu Q, Nie DY, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, Haight J, Ciamponi FE, Chen J, Duan S, Shen Y, Liu J, Marhon SA, Mehdipour P, Szewczyk MM, Dogan-Artun N, Chen W, Zhang LX, Deblois G, Prinos P, Massirer KB, Barsyte-Lovejoy D, Jin J, De Carvalho DD, Haibe-Kains B, Wang X, Cescon DW, Lupien M, Arrowsmith CH. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat Chem Biol 2022. [PMID: 35578032 DOI: 10.1038/s41589-022-01024-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Voutsadakis IA. Cell line models for drug discovery in PIK3CA-mutated colorectal cancers. Med Oncol 2022;39:89. [PMID: 35568775 DOI: 10.1007/s12032-022-01695-y] [Reference Citation Analysis]
19 Ren W, Zhang X, Li Q, Pu C, Zhang D, Teekaraman Y. Activating IL-6/STAT3 Enhances Protein Stability of Proteasome 20S α+β in Colorectal Cancer by miR-1254. BioMed Research International 2022;2022:1-18. [DOI: 10.1155/2022/4250013] [Reference Citation Analysis]
20 Li Z, Spoelstra NS, Sikora MJ, Sams SB, Elias A, Richer JK, Lee AV, Oesterreich S. Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. NPJ Breast Cancer 2022;8:62. [PMID: 35538119 DOI: 10.1038/s41523-022-00426-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Kong Y, Akatsuka S, Motooka Y, Zheng H, Cheng Z, Shiraki Y, Mashimo T, Imaoka T, Toyokuni S. BRCA1 haploinsufficiency promotes chromosomal amplification under fenton reaction-based carcinogenesis through ferroptosis-resistance. Redox Biology 2022. [DOI: 10.1016/j.redox.2022.102356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Shahzad M, Tahir MA, Khan MA, Jiang R, Malick RAS. EBSRMF: Ensemble based similarity-regularized matrix factorization to predict anticancer drug responses. IFS 2022. [DOI: 10.3233/jifs-212867] [Reference Citation Analysis]
23 Li Z, McGinn O, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Onkar S, Lampenfeld C, Sartorius CA, Miller L, Rosenzweig M, Cohen O, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Bruno TC, Vignali DAA, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation. Nat Commun 2022;13:2011. [PMID: 35440136 DOI: 10.1038/s41467-022-29498-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Lee S, Osmanbeyoglu HU. Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.. [DOI: 10.1101/2022.04.08.487589] [Reference Citation Analysis]
25 Koh MZ, Ho WY, Yeap SK, Ali NM, Yong CY, Boo L, Alitheen NB. Exosomal-microRNA transcriptome profiling of Parental and CSC-like MDA-MB-231 cells in response to cisplatin treatment. Pathol Res Pract 2022;233:153854. [PMID: 35398617 DOI: 10.1016/j.prp.2022.153854] [Reference Citation Analysis]
26 Krill-burger JM, Dempster JM, Borah AA, Paolella BR, Root DE, Golub TR, Boehm JS, Hahn WC, Mcfarland JM, Vazquez F, Tsherniak A. Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal.. [DOI: 10.1101/2022.03.02.482624] [Reference Citation Analysis]
27 Elangovan A, Hooda J, Savariau L, Puthanmadhomnarayanan S, Yates ME, Chen J, Brown DD, Mcauliffe PF, Oesterreich S, Atkinson JM, Lee AV. Loss of E-cadherin Induces IGF1R Activation Revealing a Targetable Pathway in Invasive Lobular Breast Carcinoma.. [DOI: 10.1101/2022.02.22.480917] [Reference Citation Analysis]
28 Maldonado E, Morales-Pison S, Urbina F, Jara L, Solari A. Role of the Mediator Complex and MicroRNAs in Breast Cancer Etiology. Genes (Basel) 2022;13:234. [PMID: 35205279 DOI: 10.3390/genes13020234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Hu R, Wang WL, Yang YY, Hu XT, Wang QW, Zuo WQ, Xu Y, Feng Q, Wang NY. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. Eur J Med Chem 2022;227:113922. [PMID: 34700270 DOI: 10.1016/j.ejmech.2021.113922] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
30 Sharda S, Awasthi A, Bose S, Kaur N. Cellular Interactions Networking in Interactive Models of Diseases. Handbook of Animal Models and its Uses in Cancer Research 2022. [DOI: 10.1007/978-981-19-1282-5_4-1] [Reference Citation Analysis]
31 Claridge SE, Cavallo J, Hopkins BD. Patient-Derived In Vitro and In Vivo Models of Cancer. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-030-91836-1_12] [Reference Citation Analysis]
32 Zhang J, Tang P, Zou L, Zhang J, Chen J, Yang C, He G, Liu B, Liu J, Chiang CM, Wang G, Ye T, Ouyang L. Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy. J Med Chem 2021;64:18025-53. [PMID: 34908415 DOI: 10.1021/acs.jmedchem.1c01382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
33 Lauko A, Volovetz J, Turaga SM, Bayik D, Silver DJ, Mitchell K, Mulkearns-hubert EE, Watson DC, Desai K, Midha M, Hao J, Mccortney K, Steffens A, Naik U, Ahluwalia MS, Bao S, Horbinski C, Yu J, Lathia JD. SerpinB3 drives cancer stem cell survival in glioblastoma.. [DOI: 10.1101/2021.12.21.473663] [Reference Citation Analysis]
34 Dempster JM, Boyle I, Vazquez F, Root DE, Boehm JS, Hahn WC, Tsherniak A, McFarland JM. Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects. Genome Biol 2021;22:343. [PMID: 34930405 DOI: 10.1186/s13059-021-02540-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 22.0] [Reference Citation Analysis]
35 Jones JA, McMahon NP, Zheng T, Eng J, Chin K, Kwon S, Nederlof MA, Gray JW, Gibbs SL. Oligonucleotide conjugated antibody strategies for cyclic immunostaining. Sci Rep 2021;11:23844. [PMID: 34903759 DOI: 10.1038/s41598-021-03135-9] [Reference Citation Analysis]
36 Singh L, Roy S, Kumar A, Rastogi S, Kumar D, Ansari MN, Saeedan AS, Singh M, Kaithwas G. Repurposing Combination Therapy of Voacamine With Vincristine for Downregulation of Hypoxia-Inducible Factor-1α/Fatty Acid Synthase Co-axis and Prolyl Hydroxylase-2 Activation in ER+ Mammary Neoplasia. Front Cell Dev Biol 2021;9:736910. [PMID: 34869321 DOI: 10.3389/fcell.2021.736910] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Cheng X, Zhao JX, Dong F, Cao XC. ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target. Front Oncol 2021;11:759577. [PMID: 34804958 DOI: 10.3389/fonc.2021.759577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Estoppey D, Schutzius G, Kolter C, Salathe A, Wunderlin T, Meyer A, Nigsch F, Bouwmeester T, Hoepfner D, Kirkland S. Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity. iScience 2021;24:103323. [PMID: 34805786 DOI: 10.1016/j.isci.2021.103323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chen P, Zhang X, Ding R, Yang L, Lyu X, Zeng J, Lei JH, Wang L, Bi J, Shao N, Shu D, Wu B, Wu J, Yang Z, Wang H, Wang B, Xiong K, Lu Y, Fu S, Choi TK, Lon NW, Zhang A, Tang D, Quan Y, Meng Y, Miao K, Sun H, Zhao M, Bao J, Zhang L, Xu X, Shi Y, Lin Y, Deng C. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer. Adv Sci (Weinh) 2021;8:e2101176. [PMID: 34605222 DOI: 10.1002/advs.202101176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
40 Cottrell KA, Torres LS, Dizon MG, Weber JD. 8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR. Cancer Res Commun 2021;1:56-64. [PMID: 35586115 DOI: 10.1158/2767-9764.crc-21-0027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Yuan C, Chen G, Jing C, Liu M, Liang B, Gong G, Yu M. Eriocitrin, a dietary flavonoid suppressed cell proliferation, induced apoptosis through modulation of JAK2/STAT3 and JNK/p38 MAPKs signaling pathway in MCF-7 cells. J Biochem Mol Toxicol 2021;:e22943. [PMID: 34724282 DOI: 10.1002/jbt.22943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Hu J, Lai Y, Huang H, Ramakrishnan S, Pan Y, Ma VWS, Cheuk W, So GYK, He Q, Geoffrey Lau C, Zhang L, Cho WCS, Chan KM, Wang X, Rebecca Chin Y. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis. Br J Cancer 2021. [PMID: 34718356 DOI: 10.1038/s41416-021-01596-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Sit D, Zhao B, Chen KT, Lohrisch C, Olson R, Nichol A, Hsu F. The Effect of Breast Cancer Subtype on Symptom Improvement Following Palliative Radiotherapy for Bone Metastases. Clin Oncol (R Coll Radiol) 2021:S0936-6555(21)00361-7. [PMID: 34690008 DOI: 10.1016/j.clon.2021.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Gabor A, Tognetti M, Driessen A, Tanevski J, Guo B, Cao W, Shen H, Yu T, Chung V, Bodenmiller B, Saez-Rodriguez J; Single Cell Signaling in Breast Cancer DREAM Consortium members. Cell-to-cell and type-to-type heterogeneity of signaling networks: insights from the crowd. Mol Syst Biol 2021;17:e10402. [PMID: 34661974 DOI: 10.15252/msb.202110402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Jain N, Mitre I, Nitisa D, Pirsko V, Cakstina-Dzerve I. Identification of Novel Endogenous Controls for qPCR Normalization in SK-BR-3 Breast Cancer Cell Line. Genes (Basel) 2021;12:1631. [PMID: 34681026 DOI: 10.3390/genes12101631] [Reference Citation Analysis]
46 Jung J, Hwang Y, Ahn H, Lee S, Yoo S. Precise Characterization of Genetic Interactions in Cancer via Molecular Network Refining Processes. Int J Mol Sci 2021;22:11114. [PMID: 34681774 DOI: 10.3390/ijms222011114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ghosh M, Das S. PRAMEF2-mediated dynamic regulation of YAP signaling promotes tumorigenesis. Proc Natl Acad Sci U S A 2021;118:e2105523118. [PMID: 34593639 DOI: 10.1073/pnas.2105523118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Li W, Wu H, Sui S, Wang Q, Xu S, Pang D. Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way. Front Cell Dev Biol 2021;9:736935. [PMID: 34595180 DOI: 10.3389/fcell.2021.736935] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
49 Kuzmin E, Monlong J, Martinez C, Kuasne H, Kleinman CL, Ragoussis J, Bourque G, Park M. Inferring Copy Number from Triple-Negative Breast Cancer Patient Derived Xenograft scRNAseq Data Using scCNA. Methods Mol Biol 2021;2381:285-303. [PMID: 34590283 DOI: 10.1007/978-1-0716-1740-3_16] [Reference Citation Analysis]
50 Wang X, Vizeacoumar FS, Sahu AD. INCISOR: An Algorithm to Identify Synthetic Rescue Mediators of Resistance to Targeted and Immunotherapy. Methods Mol Biol 2021;2381:203-15. [PMID: 34590278 DOI: 10.1007/978-1-0716-1740-3_11] [Reference Citation Analysis]
51 Wu X, Yang X, Xiong Y, Li R, Ito T, Ahmed TA, Karoulia Z, Adamopoulos C, Wang H, Wang L, Xie L, Liu J, Ueberheide B, Aaronson SA, Chen X, Buchanan SG, Sellers WR, Jin J, Poulikakos PI. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nat Cancer 2021;2:429-43. [PMID: 34568836 DOI: 10.1038/s43018-021-00174-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
52 Tercan B, Qin G, Kim T, Aguilar B, Kemp CJ, Chambwe N, Shmulevich I. SL-Cloud: A Computational Resource to Support Synthetic Lethal Interaction Discovery.. [DOI: 10.1101/2021.09.18.459450] [Reference Citation Analysis]
53 Carpenter S, Conlan RS. Clinical Functional Genomics. Cancers (Basel) 2021;13:4627. [PMID: 34572854 DOI: 10.3390/cancers13184627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Schachter NF, Adams JR, Skowron P, Kozma KJ, Lee CA, Raghuram N, Yang J, Loch AJ, Wang W, Kucharczuk A, Wright KL, Quintana RM, An Y, Dotzko D, Gorman JL, Wojtal D, Shah JS, Leon-Gomez P, Pellecchia G, Dupuy AJ, Perou CM, Ben-Porath I, Karni R, Zacksenhaus E, Woodgett JR, Done SJ, Garzia L, Sorana Morrissy A, Reimand J, Taylor MD, Egan SE. Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer. Nat Commun 2021;12:5238. [PMID: 34475389 DOI: 10.1038/s41467-021-25467-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
55 Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim J, Kim B, Cho E, Chang S, Lee J, Choi JK. Aberrant transcript usage induces homologous recombination deficiency and predicts therapeutic responses.. [DOI: 10.1101/2021.08.31.21262939] [Reference Citation Analysis]
56 Takashima M, Lalonde C, Olszanski LA, Zhao FQ. Localized and Systemic Inflammatory Mediators in a Murine Acute Mastitis Model. J Inflamm Res 2021;14:4053-67. [PMID: 34456581 DOI: 10.2147/JIR.S313799] [Reference Citation Analysis]
57 Voutsadakis IA. Cell Models for Chromosome 20q11.21 Amplification and Drug Sensitivities in Colorectal Cancer. Medicina (Kaunas) 2021;57:860. [PMID: 34577783 DOI: 10.3390/medicina57090860] [Reference Citation Analysis]
58 Chiu YC, Zheng S, Wang LJ, Iskra BS, Rao MK, Houghton PJ, Huang Y, Chen Y. Predicting and characterizing a cancer dependency map of tumors with deep learning. Sci Adv 2021;7:eabh1275. [PMID: 34417181 DOI: 10.1126/sciadv.abh1275] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
59 Raja Sree S, Kunthavai A. Hubness weighted svm ensemble for prediction of breast cancer subtypes. Technol Health Care 2021. [PMID: 34397436 DOI: 10.3233/THC-212825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Montazeri H, Coto-Llerena M, Bianco G, Zangene E, Taha-Mehlitz S, Paradiso V, Srivatsa S, de Weck A, Roma G, Lanzafame M, Bolli M, Beerenwinkel N, von Flüe M, Terracciano LM, Piscuoglio S, Ng CKY. Systematic identification of novel cancer genes through analysis of deep shRNA perturbation screens. Nucleic Acids Res 2021:gkab627. [PMID: 34313788 DOI: 10.1093/nar/gkab627] [Reference Citation Analysis]
61 Mohanty V, Wang F, Mills GB, Chen K; CTD2 Research Network. Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers. Cell Rep Med 2021;2:100349. [PMID: 34337565 DOI: 10.1016/j.xcrm.2021.100349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Halder TG, Soldi R, Sharma S. Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics. Curr Opin Oncol 2021;33:526-31. [PMID: 34280171 DOI: 10.1097/CCO.0000000000000763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
63 Gonçalves E, Segura-Cabrera A, Pacini C, Picco G, Behan FM, Jaaks P, Coker EA, van der Meer D, Barthorpe A, Lightfoot H, Mironenko T, Beck A, Richardson L, Yang W, Lleshi E, Hall J, Tolley C, Hall C, Mali I, Thomas F, Morris J, Leach AR, Lynch JT, Sidders B, Crafter C, Iorio F, Fawell S, Garnett MJ. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens. Mol Syst Biol 2020;16:e9405. [PMID: 32627965 DOI: 10.15252/msb.20199405] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 31.0] [Reference Citation Analysis]
64 Samson J, Derlipanska M, Zaheed O, Dean K. Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010. BMC Cancer 2021;21:790. [PMID: 34238275 DOI: 10.1186/s12885-021-08511-2] [Reference Citation Analysis]
65 Lopes R, Sprouffske K, Sheng C, Uijttewaal ECH, Wesdorp AE, Dahinden J, Wengert S, Diaz-Miyar J, Yildiz U, Bleu M, Apfel V, Mermet-Meillon F, Krese R, Eder M, Olsen AV, Hoppe P, Knehr J, Carbone W, Cuttat R, Waldt A, Altorfer M, Naumann U, Weischenfeldt J, deWeck A, Kauffmann A, Roma G, Schübeler D, Galli GG. Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens. Sci Adv 2021;7:eabf5733. [PMID: 34215580 DOI: 10.1126/sciadv.abf5733] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
66 Sannino S, Yates ME, Schurdak ME, Oesterreich S, Lee AV, Wipf P, Brodsky JL. Unique integrated stress response sensors regulate cancer cell susceptibility when Hsp70 activity is compromised. Elife 2021;10:e64977. [PMID: 34180400 DOI: 10.7554/eLife.64977] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
67 Dai M, Yan G, Wang N, Daliah G, Edick AM, Poulet S, Boudreault J, Ali S, Burgos SA, Lebrun JJ. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy. Nat Commun 2021;12:3055. [PMID: 34031411 DOI: 10.1038/s41467-021-23316-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
68 Cottrell KA, Torres LS, Weber JD. 8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR.. [DOI: 10.1101/2021.05.12.443853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Angus SP, Stuhlmiller TJ, Mehta G, Bevill SM, Goulet DR, Olivares-Quintero JF, East MP, Tanioka M, Zawistowski JS, Singh D, Sciaky N, Chen X, He X, Rashid NU, Chollet-Hinton L, Fan C, Soloway MG, Spears PA, Jefferys S, Parker JS, Gallagher KK, Forero-Torres A, Krop IE, Thompson AM, Murthy R, Gatza ML, Perou CM, Earp HS, Carey LA, Johnson GL. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. NPJ Breast Cancer 2021;7:51. [PMID: 33980863 DOI: 10.1038/s41523-021-00258-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
70 Tognetti M, Gabor A, Yang M, Cappelletti V, Windhager J, Rueda OM, Charmpi K, Esmaeilishirazifard E, Bruna A, de Souza N, Caldas C, Beyer A, Picotti P, Saez-Rodriguez J, Bodenmiller B. Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell Syst 2021;12:401-418.e12. [PMID: 33932331 DOI: 10.1016/j.cels.2021.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
71 García Solá ME, Stedile M, Beckerman I, Kordon EC. An Integrative Single-cell Transcriptomic Atlas of the Post-natal Mouse Mammary Gland Allows Discovery of New Developmental Trajectories in the Luminal Compartment. J Mammary Gland Biol Neoplasia 2021;26:29-42. [PMID: 33913090 DOI: 10.1007/s10911-021-09488-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
72 Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell 2021;184:2487-2502.e13. [PMID: 33857424 DOI: 10.1016/j.cell.2021.03.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
73 Villemin JP, Lorenzi C, Cabrillac MS, Oldfield A, Ritchie W, Luco RF. A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants. BMC Biol 2021;19:70. [PMID: 33845831 DOI: 10.1186/s12915-021-01002-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
74 Gabor A, Tognetti M, Driessen A, Tanevski J, Guo B, Cao W, Shen H, Yu T, Chung V, Bodenmiller B, Saez-rodriguez J, Single Cell Signaling in Breast Cancer DREAM Consortium members. Cell-to-cell and type-to-type heterogeneity of signaling networks: Insights from the crowd.. [DOI: 10.1101/2021.03.23.436603] [Reference Citation Analysis]
75 Jaiswal A, Gautam P, Pietilä EA, Timonen S, Nordström N, Akimov Y, Sipari N, Tanoli Z, Fleischer T, Lehti K, Wennerberg K, Aittokallio T. Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. Mol Syst Biol 2021;17:e9526. [PMID: 33750001 DOI: 10.15252/msb.20209526] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Shorstova T, Foulkes WD, Witcher M. Achieving clinical success with BET inhibitors as anti-cancer agents. Br J Cancer 2021;124:1478-90. [PMID: 33723398 DOI: 10.1038/s41416-021-01321-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 78] [Article Influence: 72.0] [Reference Citation Analysis]
77 Roarty K, Echeverria GV. Laboratory Models for Investigating Breast Cancer Therapy Resistance and Metastasis. Front Oncol 2021;11:645698. [PMID: 33777805 DOI: 10.3389/fonc.2021.645698] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
78 Murali VS, Ağaç Çobanoğlu D, Hsieh M, Zinn M, Malladi VS, Gesell J, Williams NS, Welf ES, Raj GV, Çobanoğlu MC. Cancer drug discovery as a low rank tensor completion problem.. [DOI: 10.1101/2021.03.08.434311] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Ege N, Bouguenina H, Tatari M, Chopra R. Phenotypic screening with target identification and validation in the discovery and development of E3 ligase modulators. Cell Chem Biol 2021;28:283-99. [PMID: 33740433 DOI: 10.1016/j.chembiol.2021.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
80 Dempster JM, Boyle I, Vazquez F, Root D, Boehm JS, Hahn WC, Tsherniak A, Mcfarland JM. Chronos: a CRISPR cell population dynamics model.. [DOI: 10.1101/2021.02.25.432728] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
81 Tang P, Zhang J, Liu J, Chiang CM, Ouyang L. Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. J Med Chem 2021;64:2419-35. [PMID: 33616410 DOI: 10.1021/acs.jmedchem.0c01487] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 38.0] [Reference Citation Analysis]
82 Khella CA, Mehta GA, Mehta RN, Gatza ML. Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. J Pers Med 2021;11:149. [PMID: 33669749 DOI: 10.3390/jpm11020149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
83 Parkhitko AA, Singh A, Hsieh S, Hu Y, Binari R, Lord CJ, Hannenhalli S, Ryan CJ, Perrimon N. Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells. PLoS Genet 2021;17:e1009354. [PMID: 33591981 DOI: 10.1371/journal.pgen.1009354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Sreekumar S, Levine KM, Sikora MJ, Chen J, Tasdemir N, Carter D, Dabbs DJ, Meier C, Basudan A, Boone D, McAuliffe PF, Jankowitz RC, Lee AV, Atkinson JM, Oesterreich S. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma. Endocrinology 2020;161:bqaa109. [PMID: 32609836 DOI: 10.1210/endocr/bqaa109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
85 Li Z, Wu Y, Bahreini A, Priedigkeit NM, Ding K, Sartorius CA, Miller L, Rosenzweig M, Wagle N, Richer JK, Muller WJ, Buluwela L, Ali S, Fang Y, Zhu L, Tseng GC, Gertz J, Atkinson JM, Lee AV, Oesterreich S. ESR1mutant breast cancers show elevated basal cytokeratins and immune activation.. [DOI: 10.1101/2020.12.29.424777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 de Santiago PR, Blanco A, Morales F, Marcelain K, Harismendy O, Sjöberg Herrera M, Armisén R. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sci 2021;268:118956. [PMID: 33383047 DOI: 10.1016/j.lfs.2020.118956] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
87 Sun S, Yang S, Hu X, Zheng C, Song H, Wang L, Shen Z, Wu ZS. Combination of Immunomagnetic Separation with Aptamer-Mediated Double Rolling Circle Amplification for Highly Sensitive Circulating Tumor Cell Detection. ACS Sens 2020;5:3870-8. [PMID: 33205648 DOI: 10.1021/acssensors.0c01082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
88 Alexander CM, Martin JA, Oxman E, Kasza I, Senn KA, Dvinge H. Alternative Splicing and Cleavage of GLUT8. Mol Cell Biol 2020;41:e00480-20. [PMID: 33077497 DOI: 10.1128/MCB.00480-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
89 Fox DB, Alvarez JV. Epithelial-to-mesenchymal transition activates Bcat1 expression to promote recurrent tumor growth.. [DOI: 10.1101/2020.12.08.416479] [Reference Citation Analysis]
90 Seo H, Tkachuk D, Ho C, Mammoliti A, Rezaie A, Madani Tonekaboni SA, Haibe-Kains B. SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology. Nucleic Acids Res 2020;48:W494-501. [PMID: 32442307 DOI: 10.1093/nar/gkaa421] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
91 Villemin J, Lorenzi C, Oldfield A, Cabrillac M, Ritchie W, Luco RF. A cell-to-patient machine learning transfer approach uncovers novel basal-like breast cancer prognostic markers amongst alternative splice variants.. [DOI: 10.1101/2020.11.12.380485] [Reference Citation Analysis]
92 Sviderskiy VO, Blumenberg L, Gorodetsky E, Karakousi TR, Hirsh N, Alvarez SW, Terzi EM, Kaparos E, Whiten GC, Ssebyala S, Tonzi P, Mir H, Neel BG, Huang TT, Adams S, Ruggles KV, Possemato R. Hyperactive CDK2 Activity in Basal-like Breast Cancer Imposes a Genome Integrity Liability that Can Be Exploited by Targeting DNA Polymerase ε. Mol Cell 2020;80:682-698.e7. [PMID: 33152268 DOI: 10.1016/j.molcel.2020.10.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
93 Diaz JEL, Barcessat V, Bahamon C, Cagan RL. Functional Exploration of Copy Number Alterations in a Drosophila Model of Triple Negative Breast Cancer.. [DOI: 10.1101/2020.10.18.343848] [Reference Citation Analysis]
94 Sundara Rajan S, Ludwig KR, Hall KL, Jones TL, Caplen NJ. Cancer biology functional genomics: From small RNAs to big dreams. Mol Carcinog 2020;59:1343-61. [PMID: 33043516 DOI: 10.1002/mc.23260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
95 Wang S, Li J, Tong W, Li H, Feng Q, Teng B. Advances in the pathogenesis and treatment of nut carcinoma: a narrative review. Transl Cancer Res 2020;9:6505-15. [PMID: 35117258 DOI: 10.21037/tcr-20-1884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Luo ML, Li J, Shen L, Chu J, Guo Q, Liang G, Wu W, Chen J, Chen R, Song E. The Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells. J Natl Cancer Inst 2020;112:356-68. [PMID: 31286138 DOI: 10.1093/jnci/djz134] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 11.5] [Reference Citation Analysis]
97 van Leeuwen J, Ba-alawi W, Branchard E, Longo J, Silvester J, Cescon DW, Haibe-kains B, Penn LZ, Gendoo DM. Computational pharmacogenomics screen identifies synergistic statin-compound combinations as anti-breast cancer therapies.. [DOI: 10.1101/2020.09.07.286922] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Mohanty V, Wang F, Mills G, Chen K. Targeting uncoupling of copy number and gene expression in cancers.. [DOI: 10.1101/2020.08.28.272641] [Reference Citation Analysis]
99 Chang CA, Jen J, Jiang S, Sayad A, Mer AS, Brown KR, Nixon A, Dhabaria A, Tang KH, Venet D, Sotiriou C, Deng J, Wong K, Adams S, Meyn P, Heguy A, Skok J, Tsirigos A, Ueberheide B, Moffat J, Singh A, Haibe-kains B, Khodadadi-jamayran A, Neel BG. Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.. [DOI: 10.1101/2020.08.28.273029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
100 Zhang K, Liu H, Song Z, Jiang Y, Kim H, Samavati L, Nguyen HM, Yang ZQ. The UPR Transducer IRE1 Promotes Breast Cancer Malignancy by Degrading Tumor Suppressor microRNAs. iScience 2020;23:101503. [PMID: 32911332 DOI: 10.1016/j.isci.2020.101503] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
101 Zhao CC, Zhan MN, Liu WT, Jiao Y, Zhang YY, Lei Y, Zhang TT, Zhang CJ, Du YY, Gu KS, Wei W. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer. Cancer Lett 2020;493:120-7. [PMID: 32829006 DOI: 10.1016/j.canlet.2020.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
102 Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, Chen W, Nie Y, Zhang LX, Vellanki RN, Zhou S, Prinos P, Wouters BG, Dirks PB, Done SJ, Park M, Cescon DW, Haibe-Kains B, Lupien M, Arrowsmith CH. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nat Commun 2020;11:4205. [PMID: 32826891 DOI: 10.1038/s41467-020-18020-8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 29.5] [Reference Citation Analysis]
103 Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The emerging role of BET inhibitors in breast cancer. Breast 2020;53:152-63. [PMID: 32827765 DOI: 10.1016/j.breast.2020.08.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
104 Suhail Y, Cain MP, Vanaja K, Kurywchak PA, Levchenko A, Kalluri R, Kshitiz. Systems Biology of Cancer Metastasis. Cell Syst 2019;9:109-27. [PMID: 31465728 DOI: 10.1016/j.cels.2019.07.003] [Cited by in Crossref: 108] [Cited by in F6Publishing: 119] [Article Influence: 54.0] [Reference Citation Analysis]
105 Marques JG, Gryder BE, Pavlovic B, Chung Y, Ngo QA, Frommelt F, Gstaiger M, Song Y, Benischke K, Laubscher D, Wachtel M, Khan J, Schäfer BW. NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. Elife 2020;9:e54993. [PMID: 32744500 DOI: 10.7554/eLife.54993] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
106 Petretich M, Demont EH, Grandi P. Domain-selective targeting of BET proteins in cancer and immunological diseases. Curr Opin Chem Biol 2020;57:184-93. [PMID: 32741705 DOI: 10.1016/j.cbpa.2020.02.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 11.5] [Reference Citation Analysis]
107 Boni J, Rubio-Perez C, López-Bigas N, Fillat C, de la Luna S. The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities. Cancers (Basel) 2020;12:E2106. [PMID: 32751160 DOI: 10.3390/cancers12082106] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
108 Spriano F, Stathis A, Bertoni F. Targeting BET bromodomain proteins in cancer: The example of lymphomas. Pharmacol Ther. 2020;215:107631. [PMID: 32693114 DOI: 10.1016/j.pharmthera.2020.107631] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
109 Tasdemir N, Ding K, Savariau L, Levine KM, Du T, Elangovan A, Bossart EA, Lee AV, Davidson NE, Oesterreich S. Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma. Sci Rep 2020;10:11487. [PMID: 32661241 DOI: 10.1038/s41598-020-68141-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
110 Zhou Y, Tang X, Niu L, Liu Y, Wang B, He J. Ectodermal-neural cortex 1 as a novel biomarker predicts poor prognosis and induces metastasis in breast cancer by promoting Wnt/β-catenin pathway. J Cell Mol Med 2020;24:8826-35. [PMID: 32618411 DOI: 10.1111/jcmm.15520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
111 Jang K, Park MJ, Park JS, Hwangbo H, Sung MK, Kim S, Jung J, Lee JW, Ahn SH, Chang S, Choi JK. Computational inference of cancer-specific vulnerabilities in clinical samples. Genome Biol 2020;21:155. [PMID: 32600395 DOI: 10.1186/s13059-020-02077-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
112 Baker LA, Holliday H, Roden D, Krisp C, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Sankaranarayanan G, Law AMK, McFarland A, Simpson PT, Lakhani S, Dodson E, Selinger C, Anderson L, Samimi G, Hacker NF, Lim E, Ormandy CJ, Naylor MJ, Simpson K, Nikolic I, O'Toole S, Kaplan W, Cowley MJ, Carroll JS, Molloy M, Swarbrick A. Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. Breast Cancer Res 2020;22:63. [PMID: 32527287 DOI: 10.1186/s13058-020-01306-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
113 Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, Shue YT, Ko JH, Lee MC, Kong C, Nomura DK, Ohlmeyer M, Swaney DL, Krogan NJ, Jackson PK, Narla G, Gordan JD, Shokat KM, Sage J. Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells. Cancer Cell 2020;38:129-143.e7. [PMID: 32531271 DOI: 10.1016/j.ccell.2020.05.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 17.0] [Reference Citation Analysis]
114 Qiu Y, Ma C, Xie H, Kingsford C. Detecting transcriptomic structural variants in heterogeneous contexts via the Multiple Compatible Arrangements Problem. Algorithms Mol Biol 2020;15:9. [PMID: 32467720 DOI: 10.1186/s13015-020-00170-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
115 Lord CJ, Quinn N, Ryan CJ. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. Elife 2020;9:e58925. [PMID: 32463358 DOI: 10.7554/eLife.58925] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
116 Carew JS, Espitia CM, Zhao W, Visconte V, Anwer F, Kelly KR, Nawrocki ST. Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity. Blood Adv 2019;3:1318-29. [PMID: 31015208 DOI: 10.1182/bloodadvances.2018026484] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
117 Hight SK, Mootz A, Kollipara RK, McMillan E, Yenerall P, Otaki Y, Li LS, Avila K, Peyton M, Rodriguez-Canales J, Mino B, Villalobos P, Girard L, Dospoy P, Larsen J, White MA, Heymach JV, Wistuba II, Kittler R, Minna JD. An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia 2020;22:294-310. [PMID: 32512502 DOI: 10.1016/j.neo.2020.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
118 Geng W, Song H, Zhao Q, Dong K, Pu Q, Gao H, Lv Y. miR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer. Biomed Res Int 2020;2020:9512793. [PMID: 32775453 DOI: 10.1155/2020/9512793] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
119 Bhatia S, Blick T, Pinto C, Waltham M, Monkman J, Ivanova E, Pollock PM, Nagaraj SH, Wiegmans AP, Haviv I, Simpson KJ, Thompson EW. Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen. Cancers (Basel) 2020;12:E1123. [PMID: 32365878 DOI: 10.3390/cancers12051123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
120 Li T, Zhou X, Wang J, Liu Z, Han S, Wan L, Sun X, Chen H. Adipose-derived mesenchymal stem cells and extracellular vesicles confer antitumor activity in preclinical treatment of breast cancer. Pharmacol Res 2020;157:104843. [PMID: 32360582 DOI: 10.1016/j.phrs.2020.104843] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
121 Jiang Y, Guo X, Liu L, Rode S, Wang R, Liu H, Yang ZQ. Metagenomic characterization of lysine acetyltransferases in human cancer and their association with clinicopathologic features. Cancer Sci 2020;111:1829-39. [PMID: 32162442 DOI: 10.1111/cas.14385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
122 Knowlson C, Haddock P, Bingham V, McQuaid S, Mullan PB, Buckley NE. Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer. Ther Adv Med Oncol 2020;12:1758835920906047. [PMID: 32215056 DOI: 10.1177/1758835920906047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
123 Khandekar D, Tiriveedhi V. Role of BET Inhibitors in Triple Negative Breast Cancers. Cancers (Basel) 2020;12:E784. [PMID: 32218352 DOI: 10.3390/cancers12040784] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
124 Zaheed O, Samson J, Dean K. A bioinformatics approach to identify novel long, non-coding RNAs in breast cancer cell lines from an existing RNA-sequencing dataset. Noncoding RNA Res 2020;5:48-59. [PMID: 32206740 DOI: 10.1016/j.ncrna.2020.02.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
125 Chen F, Ding K, Priedigkeit N, Elangovan A, Levine KM, Carleton N, Savariau L, Atkinson JM, Oesterreich S, Lee AV. Single cell transcriptomic heterogeneity in invasive ductal and lobular breast cancer cells.. [DOI: 10.1101/2020.02.21.959023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Mei AH, Tung K, Han J, Perumal D, Laganà A, Keats J, Auclair D, Chari A, Jagannath S, Parekh S, Cho HJ. MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1. Oncotarget 2020;11:727-39. [PMID: 32133047 DOI: 10.18632/oncotarget.27488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
127 Kung C, Cottrell KA, Ryu S, Bramel ER, Kladney RD, Bross EA, Maggi L, Weber JD. ADAR1 editing dependency in triple-negative breast cancer.. [DOI: 10.1101/2020.01.31.928911] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Jaiswal A, Gautam P, Pietilä EA, Timonen S, Nordström N, Sipari N, Tanoli Z, Lehti K, Wennerberg K, Aittokallio T. Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor.. [DOI: 10.1101/2020.01.31.929372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Selitsky SR, Marron D, Hollern D, Mose LE, Hoadley KA, Jones C, Parker JS, Dittmer DP, Perou CM. Virus expression detection reveals RNA-sequencing contamination in TCGA. BMC Genomics 2020;21:79. [PMID: 31992194 DOI: 10.1186/s12864-020-6483-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
130 Tognetti M, Gabor A, Yang M, Cappelletti V, Windhager J, Charmpi K, de Souza N, Beyer A, Picotti P, Saez-rodriguez J, Bodenmiller B. Deciphering the Signaling Network Landscape of Breast Cancer Improves Drug Sensitivity Prediction.. [DOI: 10.1101/2020.01.21.907691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Manning M, Jiang Y, Wang R, Liu L, Rode S, Bonahoom M, Kim S, Yang ZQ. Pan-cancer analysis of RNA methyltransferases identifies FTSJ3 as a potential regulator of breast cancer progression. RNA Biol 2020;17:474-86. [PMID: 31957540 DOI: 10.1080/15476286.2019.1708549] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
132 Gonçalves E, Segura-cabrera A, Pacini C, Picco G, Behan FM, Jaaks P, Coker EA, van der Meer D, Barthorpe A, Lightfoot H, Leach AR, Lynch JT, Sidders B, Crafter C, Iorio F, Fawell S, Garnett MJ, GDSC Screening Team. Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.. [DOI: 10.1101/2020.01.14.905729] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Cui JJ, Wang LY, Tan ZR, Zhou HH, Zhan X, Yin JY. MASS SPECTROMETRY-BASED PERSONALIZED DRUG THERAPY. Mass Spectrom Rev 2020;39:523-52. [PMID: 31904155 DOI: 10.1002/mas.21620] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
134 Hernández-lemus E. A personalized medicine approach to drug repurposing for the treatment of breast cancer molecular subtypes. Drug Repurposing in Cancer Therapy 2020. [DOI: 10.1016/b978-0-12-819668-7.00007-5] [Reference Citation Analysis]
135 Akbar MW, Isbilen M, Belder N, Canli SD, Kucukkaraduman B, Turk C, Sahin O, Gure AO. A Stemness and EMT Based Gene Expression Signature Identifies Phenotypic Plasticity and is A Predictive but Not Prognostic Biomarker for Breast Cancer. J Cancer 2020;11:949-61. [PMID: 31949498 DOI: 10.7150/jca.34649] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
136 Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M. Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy. J Clin Med 2019;9:E64. [PMID: 31888054 DOI: 10.3390/jcm9010064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
137 Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty MD, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K. TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Rep 2018;25:1255-1267.e5. [PMID: 30380416 DOI: 10.1016/j.celrep.2018.10.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
138 Romero Y, Wise R, Zolkiewska A. Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells. Cancer Immunol Immunother 2020;69:43-55. [PMID: 31796994 DOI: 10.1007/s00262-019-02437-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
139 Pathria G, Lee JS, Hasnis E, Tandoc K, Scott DA, Verma S, Feng Y, Larue L, Sahu AD, Topisirovic I, Ruppin E, Ronai ZA. Translational reprogramming marks adaptation to asparagine restriction in cancer. Nat Cell Biol 2019;21:1590-603. [PMID: 31740775 DOI: 10.1038/s41556-019-0415-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
140 Li X, Song X, Ma J, Zhao Y, Jiang Q, Zhao Z, Li M. FSIP1 is correlated with estrogen receptor status and poor prognosis. Mol Carcinog 2020;59:126-35. [DOI: 10.1002/mc.23134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Shaikh I, Ansari A, Ayachit G, Gandhi M, Sharma P, Bhairappanavar S, Joshi CG, Das J. Differential gene expression analysis of HNSCC tumors deciphered tobacco dependent and independent molecular signatures. Oncotarget 2019;10:6168-83. [PMID: 31692905 DOI: 10.18632/oncotarget.27249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
142 Montazeri H, Coto-llerena M, Bianco G, Zangene E, Taha-mehlitz S, Paradiso V, Srivatsa S, de Weck A, Roma G, Lanzafame M, Bolli M, Beerenwinkel N, von Flüe M, Terracciano LM, Piscuoglio S, Ng CKY. Systematic Identification of Novel Cancer Genes through Analysis of Deep shRNA Perturbation Screens.. [DOI: 10.1101/807248] [Reference Citation Analysis]
143 Lanneau C, Kalouche G, Cai X, Lo‐presti F, Potting C. Genetic Manipulation/Modulation for Target Discovery and Validation. Methods and Principles in Medicinal Chemistry 2019. [DOI: 10.1002/9783527818242.ch9] [Reference Citation Analysis]
144 Wu Q, ba-alawi W, Deblois G, Cruickshank J, Duan S, Lima-fernandes E, Haight J, Tonekaboni SAM, Fortier A, Kuasne H, Mckee TD, Mahmoud H, Cameron S, Dogan-artun N, Chen W, Vellanki RN, Zhou S, Done SJ, Park M, Cescon DW, Haibe-kains B, Lupien M, Arrowsmith CH. GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer.. [DOI: 10.1101/764944] [Reference Citation Analysis]
145 Mammoliti A, Smirnov P, Safikhani Z, Ba-Alawi W, Haibe-Kains B. Creating reproducible pharmacogenomic analysis pipelines. Sci Data 2019;6:166. [PMID: 31481707 DOI: 10.1038/s41597-019-0174-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
146 Bleu M, Gaulis S, Lopes R, Sprouffske K, Apfel V, Holwerda S, Pregnolato M, Yildiz U, Cordoʹ V, Dost AFM, Knehr J, Carbone W, Lohmann F, Lin CY, Bradner JE, Kauffmann A, Tordella L, Roma G, Galli GG. PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma. Nat Commun 2019;10:3739. [PMID: 31431624 DOI: 10.1038/s41467-019-11672-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
147 Lenoir WF, Lim TL, Hart T. PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens. Nucleic Acids Res 2018;46:D776-80. [PMID: 29077937 DOI: 10.1093/nar/gkx993] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 21.0] [Reference Citation Analysis]
148 Nair NU, Das A, Rogkoti VM, Fokkelman M, Marcotte R, de Jong CG, Koedoot E, Lee JS, Meilijson I, Hannenhalli S, Neel BG, de Water BV, Le Dévédec SE, Ruppin E. Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival. Sci Rep 2019;9:10989. [PMID: 31358840 DOI: 10.1038/s41598-019-47440-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
149 Lazar IM, Karcini A, Ahuja S, Estrada-Palma C. Proteogenomic Analysis of Protein Sequence Alterations in Breast Cancer Cells. Sci Rep 2019;9:10381. [PMID: 31316139 DOI: 10.1038/s41598-019-46897-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
150 Kang GJ, Park MK, Byun HJ, Kim HJ, Kim EJ, Yu L, Kim B, Shim JG, Lee H, Lee CH. SARNP, a participant in mRNA splicing and export, negatively regulates E-cadherin expression via interaction with pinin. J Cell Physiol 2020;235:1543-55. [PMID: 31313837 DOI: 10.1002/jcp.29073] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
151 Cochran AG, Conery AR, Sims RJ 3rd. Bromodomains: a new target class for drug development. Nat Rev Drug Discov 2019;18:609-28. [PMID: 31273347 DOI: 10.1038/s41573-019-0030-7] [Cited by in Crossref: 215] [Cited by in F6Publishing: 223] [Article Influence: 71.7] [Reference Citation Analysis]
152 Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Res Treat 2019;177:369-82. [PMID: 31254157 DOI: 10.1007/s10549-019-05329-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
153 Kiblawi S, Chasman D, Henning A, Park E, Poon H, Gould M, Ahlquist P, Craven M. Augmenting subnetwork inference with information extracted from the scientific literature. PLoS Comput Biol 2019;15:e1006758. [PMID: 31246951 DOI: 10.1371/journal.pcbi.1006758] [Reference Citation Analysis]
154 Cai H, Everett RS, Thakker DR. Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours. Br J Pharmacol 2019;176:2724-35. [PMID: 31032880 DOI: 10.1111/bph.14694] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
155 Pietilä M, Sahgal P, Peuhu E, Jäntti NZ, Paatero I, Närvä E, Al-Akhrass H, Lilja J, Georgiadou M, Andersen OM, Padzik A, Sihto H, Joensuu H, Blomqvist M, Saarinen I, Boström PJ, Taimen P, Ivaska J. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun 2019;10:2340. [PMID: 31138794 DOI: 10.1038/s41467-019-10275-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 11.7] [Reference Citation Analysis]
156 Lord CJ, Quinn N, Ryan CJ. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions.. [DOI: 10.1101/646810] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
157 Gautam P, Jaiswal A, Aittokallio T, Al-Ali H, Wennerberg K. Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets. Cell Chem Biol 2019;26:970-979.e4. [PMID: 31056464 DOI: 10.1016/j.chembiol.2019.03.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
158 Mammoliti A, Smirnov P, Safikhani Z, Ba-alawi W, Haibe-kains B. Creating reproducible pharmacogenomic analysis pipelines.. [DOI: 10.1101/614560] [Reference Citation Analysis]
159 Kim E, Dede M, Lenoir WF, Wang G, Srinivasan S, Colic M, Hart T. A network of human functional gene interactions from knockout fitness screens in cancer cells. Life Sci Alliance 2019;2:e201800278. [PMID: 30979825 DOI: 10.26508/lsa.201800278] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 19.7] [Reference Citation Analysis]
160 Wang S, Su X, Xu M, Xiao X, Li X, Li H, Keating A, Zhao RC. Exosomes secreted by mesenchymal stromal/stem cell-derived adipocytes promote breast cancer cell growth via activation of Hippo signaling pathway. Stem Cell Res Ther. 2019;10:117. [PMID: 30971292 DOI: 10.1186/s13287-019-1220-2] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 22.0] [Reference Citation Analysis]
161 Yang C, Qin C, Bai L, Wang S. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review. Drug Discovery Today: Technologies 2019;31:43-51. [DOI: 10.1016/j.ddtec.2019.04.001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 72] [Article Influence: 23.7] [Reference Citation Analysis]
162 Sahu AD, S Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, Egan RK, Damon LJ, Frederick DT, Jerby-Arnon L, Wagner A, Cheng K, Park SG, Robinson W, Gardner K, Boland G, Hannenhalli S, Herlyn M, Benes C, Flaherty K, Luo J, Gutkind JS, Ruppin E. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Mol Syst Biol 2019;15:e8323. [PMID: 30858180 DOI: 10.15252/msb.20188323] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
163 Scholl C, Fröhling S. Exploiting rare driver mutations for precision cancer medicine. Curr Opin Genet Dev 2019;54:1-6. [PMID: 30844512 DOI: 10.1016/j.gde.2019.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
164 Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell 2019;35:457-472.e5. [PMID: 30773340 DOI: 10.1016/j.ccell.2019.01.009] [Cited by in Crossref: 113] [Cited by in F6Publishing: 121] [Article Influence: 37.7] [Reference Citation Analysis]
165 Yuan W, Pang J, Guan D, Tian Y, Al-dhelaan A, Al-dhelaan M. Sign Prediction on Unlabeled Social Networks Using Branch and Bound Optimized Transfer Learning. Complexity 2019;2019:1-11. [DOI: 10.1155/2019/4906903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
166 Block I, Müller C, Sdogati D, Pedersen H, List M, Jaskot AM, Syse SD, Lund Hansen P, Schmidt S, Christiansen H, Casella C, Bering Olsen S, Blomstrøm MM, Riedel A, Thomassen M, Kruse TA, Karlskov Hansen SW, Kioschis P, Mollenhauer J. CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3. Oncogene 2019;38:4560-73. [PMID: 30755730 DOI: 10.1038/s41388-019-0739-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
167 Tasdemir N, Ding K, Levine KM, Du T, Bossart EA, Lee AV, Davidson NE, Oesterreich S. Proteomic and Transcriptomic Profiling Identifies Mediators of Anchorage-Independent Growth and Roles of Inhibitor of Differentiation Proteins in Invasive Lobular Breast Cancer.. [DOI: 10.1101/543132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
168 Gonçalves E, Behan FM, Louzada S, Arnol D, Stronach EA, Yang F, Yusa K, Stegle O, Iorio F, Garnett MJ. Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects. Genome Biol 2019;20:27. [PMID: 30722791 DOI: 10.1186/s13059-019-1637-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
169 Alexandrou S, George SM, Ormandy CJ, Lim E, Oakes SR, Caldon CE. The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. Int J Mol Sci 2019;20:E667. [PMID: 30720718 DOI: 10.3390/ijms20030667] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
170 Tseng Y, Boehm JS. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Current Opinion in Genetics & Development 2019;54:33-40. [DOI: 10.1016/j.gde.2019.02.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
171 Garrido-Castro AC, Lin NU, Polyak K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov 2019;9:176-98. [PMID: 30679171 DOI: 10.1158/2159-8290.CD-18-1177] [Cited by in Crossref: 424] [Cited by in F6Publishing: 452] [Article Influence: 141.3] [Reference Citation Analysis]
172 Lecomte S, Demay F, Pham TH, Moulis S, Efstathiou T, Chalmel F, Pakdel F. Deciphering the Molecular Mechanisms Sustaining the Estrogenic Activity of the Two Major Dietary Compounds Zearalenone and Apigenin in ER-Positive Breast Cancer Cell Lines. Nutrients 2019;11:E237. [PMID: 30678243 DOI: 10.3390/nu11020237] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
173 Schwill M, Tamaskovic R, Gajadhar AS, Kast F, White FM, Plückthun A. Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer. Sci Signal 2019;12:eaau2875. [PMID: 30670633 DOI: 10.1126/scisignal.aau2875] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
174 Qiao X, Liu Y, Prada ML, Gupta A, Jaiswal A, Sharma M, Haikala H, Talvinen K, Yetukuri L, Pylvänäinen JW, Klefström J, Kronqvist P, Meinander A, Aittokallio T, Hietakangas V, Eilers M, Westermarck J. Control of MYC-dependent apoptotic threshold by a co-amplified ubiquitin E3 ligase UBR5.. [DOI: 10.1101/515247] [Reference Citation Analysis]
175 Hu ZT, Ye Y, Newbury PA, Huang H, Chen B. AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets. Pac Symp Biocomput 2019;24:248-59. [PMID: 30864327] [Reference Citation Analysis]
176 Zhou J, Chen WR, Yang LC, Wang J, Sun JY, Zhang WW, He ZY, Wu SG. KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer. Cancer Res Treat 2019;51:1207-21. [PMID: 30590004 DOI: 10.4143/crt.2018.460] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
177 Parameswaran S, Kundapur D, Vizeacoumar FS, Freywald A, Uppalapati M, Vizeacoumar FJ. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality. Trends Cancer 2019;5:11-29. [PMID: 30616753 DOI: 10.1016/j.trecan.2018.11.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
178 Fröhlich F, Kessler T, Weindl D, Shadrin A, Schmiester L, Hache H, Muradyan A, Schütte M, Lim J, Heinig M, Theis FJ, Lehrach H, Wierling C, Lange B, Hasenauer J. Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model. Cell Systems 2018;7:567-579.e6. [DOI: 10.1016/j.cels.2018.10.013] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 17.8] [Reference Citation Analysis]
179 McFarland JM, Ho ZV, Kugener G, Dempster JM, Montgomery PG, Bryan JG, Krill-Burger JM, Green TM, Vazquez F, Boehm JS, Golub TR, Hahn WC, Root DE, Tsherniak A. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat Commun 2018;9:4610. [PMID: 30389920 DOI: 10.1038/s41467-018-06916-5] [Cited by in Crossref: 209] [Cited by in F6Publishing: 214] [Article Influence: 52.3] [Reference Citation Analysis]
180 Campbell J, Ryan CJ, Lord CJ. Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels. Methods Mol Biol 2018;1711:83-99. [PMID: 29344886 DOI: 10.1007/978-1-4939-7493-1_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
181 Wang Y, Li BB, Li J, Roberts TM, Zhao JJ. A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. iScience 2018;9:149-60. [PMID: 30391850 DOI: 10.1016/j.isci.2018.10.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
182 Wang S, Ma J, Zhang W, Shen JP, Huang J, Peng J, Ideker T. Typing tumors using pathways selected by somatic evolution. Nat Commun 2018;9:4159. [PMID: 30297789 DOI: 10.1038/s41467-018-06464-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
183 Sagredo EA, Blanco A, Sagredo AI, Pérez P, Sepúlveda-Hermosilla G, Morales F, Müller B, Verdugo R, Marcelain K, Harismendy O, Armisén R. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 2018;51:36. [PMID: 30290838 DOI: 10.1186/s40659-018-0185-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
184 Tu WB, Shiah Y, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-alawi W, Aman A, Al-awar R, Cescon DW, Haibe-kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ. MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. Cancer Cell 2018;34:579-595.e8. [DOI: 10.1016/j.ccell.2018.09.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 16.3] [Reference Citation Analysis]
185 Tasdemir N, Bossart EA, Li Z, Zhu L, Sikora MJ, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res 2018;78:6209-22. [PMID: 30228172 DOI: 10.1158/0008-5472.CAN-18-1416] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
186 Zeng Y, Zhou Y, Zheng F. Data skyline query protocol based on parallel genetic improvement decision tree. J Supercomput 2020;76:1116-27. [DOI: 10.1007/s11227-018-2593-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Luo J, Feng J, Wen Q, Qoyawayma C, Wang W, Chen L, Lu J, Zhan Y, Xu L, Zang H, Fan S, Chu S. Elevated expression of IRS-1 associates with phosphorylated Akt expression and predicts poor prognosis of breast invasive ductal carcinoma. Human Pathology 2018;79:9-17. [DOI: 10.1016/j.humpath.2018.03.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
188 Luk IY, Reehorst CM, Mariadason JM. ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer. Molecules 2018;23:E2191. [PMID: 30200227 DOI: 10.3390/molecules23092191] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 12.5] [Reference Citation Analysis]
189 Mabe NW, Fox DB, Lupo R, Decker AE, Phelps SN, Thompson JW, Alvarez JV. Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer. J Clin Invest 2018;128:4413-28. [PMID: 30148456 DOI: 10.1172/JCI99481] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
190 Liao S, Maertens O, Cichowski K, Elledge SJ. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is. Genes Dev 2018;32:1188-200. [PMID: 30135075 DOI: 10.1101/gad.315648.118] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
191 Shi J, Song S, Han H, Xu H, Huang M, Qian C, Zhang X, Ouyang L, Hong Y, Zhuang W, Li B. Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma. Mol Pharm 2018;15:4139-47. [PMID: 30048594 DOI: 10.1021/acs.molpharmaceut.8b00554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
192 Tom Hu Z, Ye Y, Newbury PA, Huang H, Chen B. AICM: A Genuine Framework for Correcting Inconsistency Between Large Pharmacogenomics Datasets.. [DOI: 10.1101/386896] [Reference Citation Analysis]
193 Aguirre AJ, Hahn WC. Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med 2018;8:a031518. [PMID: 29101114 DOI: 10.1101/cshperspect.a031518] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
194 Nair NU, Das A, Rogkoti V, Fokkelman M, Marcotte R, de Jong CG, Lee JS, Meilijson I, Hannenhalli S, Neel BG, van de Water B, Le Dévédec SE, Ruppin E. Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival.. [DOI: 10.1101/379123] [Reference Citation Analysis]
195 Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, Araki K, Ozerdem U, Simeone DM, Miller G, Neel BG, Tang KH. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discov 2018;8:1237-49. [PMID: 30045908 DOI: 10.1158/2159-8290.CD-18-0444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, Araki K, Ozerdem U, Simeone DM, Miller G, Neel BG, Tang KH. SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. Cancer Discov 2018;8:1237-49. [PMID: 30045908 DOI: 10.1158/2159-8290.CD-18-0444] [Cited by in Crossref: 150] [Cited by in F6Publishing: 156] [Article Influence: 37.5] [Reference Citation Analysis]
197 Ye IC, Fertig EJ, DiGiacomo JW, Considine M, Godet I, Gilkes DM. Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes. Mol Cancer Res 2018;16:1889-901. [PMID: 30037853 DOI: 10.1158/1541-7786.MCR-18-0345] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
198 Xiao T, Li W, Wang X, Xu H, Yang J, Wu Q, Huang Y, Geradts J, Jiang P, Fei T, Chi D, Zang C, Liao Q, Rennhack J, Andrechek E, Li N, Detre S, Dowsett M, Jeselsohn RM, Liu XS, Brown M. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc Natl Acad Sci U S A 2018;115:7869-78. [PMID: 29987050 DOI: 10.1073/pnas.1722617115] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 9.5] [Reference Citation Analysis]
199 Lee JS, Das A, Jerby-Arnon L, Arafeh R, Auslander N, Davidson M, McGarry L, James D, Amzallag A, Park SG, Cheng K, Robinson W, Atias D, Stossel C, Buzhor E, Stein G, Waterfall JJ, Meltzer PS, Golan T, Hannenhalli S, Gottlieb E, Benes CH, Samuels Y, Shanks E, Ruppin E. Harnessing synthetic lethality to predict the response to cancer treatment. Nat Commun 2018;9:2546. [PMID: 29959327 DOI: 10.1038/s41467-018-04647-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 16.3] [Reference Citation Analysis]
200 Anufrieva KS, Shender VО, Arapidi GP, Pavlyukov MS, Shakhparonov MI, Shnaider PV, Butenko IO, Lagarkova MA, Govorun VM. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells. Genome Med 2018;10:49. [PMID: 29950180 DOI: 10.1186/s13073-018-0557-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
201 Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, Katz TA, Boone DN, Jacobsen BM, Atkinson JM, Oesterreich S, Lee AV. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res 2018;24:5165-77. [PMID: 29941485 DOI: 10.1158/1078-0432.CCR-18-0279] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
202 Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ. Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. Oncogene 2018;37:5701-18. [PMID: 29915391 DOI: 10.1038/s41388-018-0368-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
203 Tasdemir N, Bossart E, Li Z, Li Z, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S. Comprehensive 2D and 3D phenotypic characterization of human invasive lobular carcinoma cell lines.. [DOI: 10.1101/341313] [Reference Citation Analysis]
204 Xin X, Teng C, Du X, Lv Y, Xiao Q, Wu Y, He W, Yin L. Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route. Theranostics 2018;8:3474-89. [PMID: 30026860 DOI: 10.7150/thno.23804] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
205 Girnius N, Edwards YJ, Garlick DS, Davis RJ. The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation. Elife 2018;7:e36389. [PMID: 29856313 DOI: 10.7554/eLife.36389] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
206 Gonçalves E, Behan FM, Louzada S, Arnol D, Stronach E, Yang F, Yusa K, Stegle O, Iorio F, Garnett MJ. Tandem duplications lead to loss of fitness effects in CRISPR-Cas9 data.. [DOI: 10.1101/325076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
207 Kim E, Dede M, Lenoir WF, Wang G, Srinivasan S, Colic M, Hart T. Hierarchical organization of the human cell from a cancer coessentiality network.. [DOI: 10.1101/328880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
208 Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene 2018;37:4611-25. [PMID: 29760405 DOI: 10.1038/s41388-018-0300-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]
209 Ma L, Liang Z, Zhou H, Qu L. Applications of RNA Indexes for Precision Oncology in Breast Cancer. Genomics Proteomics Bioinformatics 2018;16:108-19. [PMID: 29753129 DOI: 10.1016/j.gpb.2018.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
210 Ma C, Shao M, Kingsford C. SQUID: transcriptomic structural variation detection from RNA-seq. Genome Biol 2018;19:52. [PMID: 29650026 DOI: 10.1186/s13059-018-1421-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
211 Pietilä M, Sahgal P, Peuhu E, Jäntti N, Paatero I, Andersen OM, Padzik A, Blomqvist M, Saarinen I, Boström P, Taimen P, Ivaska J. SORLA-driven endosomal trafficking regulates the oncogenic fitness of HER2.. [DOI: 10.1101/299586] [Reference Citation Analysis]
212 Hüllein J, Słabicki M, Rosolowski M, Jethwa A, Habringer S, Tomska K, Kurilov R, Lu J, Scheinost S, Wagener R, Huang Z, Lukas M, Yavorska O, Helferich H, Scholtysik R, Bonneau K, Tedesco D, Küppers R, Klapper W, Pott C, Stilgenbauer S, Burkhardt B, Löffler M, Trümper L, Hummel M, Brors B, Zapatka M, Siebert R, Keller U, Huber W, Kreuz M, Zenz T, consortium MMML. MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphoma.. [DOI: 10.1101/289363] [Reference Citation Analysis]
213 Zhong Z, Rosenow M, Xiao N, Spetzler D. Profiling plasma extracellular vesicle by pluronic block-copolymer based enrichment method unveils features associated with breast cancer aggression, metastasis and invasion. J Extracell Vesicles 2018;7:1458574. [PMID: 29696079 DOI: 10.1080/20013078.2018.1458574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
214 Chen Y, Zhang Y, Guo X. Proteasome dysregulation in human cancer: implications for clinical therapies. Cancer Metastasis Rev 2017;36:703-16. [PMID: 29039081 DOI: 10.1007/s10555-017-9704-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
215 Tang YC, Ho SC, Tan E, Ng AWT, McPherson JR, Goh GYL, Teh BT, Bard F, Rozen SG. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. Breast Cancer Res 2018;20:22. [PMID: 29566768 DOI: 10.1186/s13058-018-0949-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
216 Das A, Lee JS, Zhang G, Wang Z, Iglesias-bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, Egan RK, Damon LJ, Frederick DT, Wagner A, Cheng K, Park SG, Robinson W, Gardner K, Boland G, Hannenhalli S, Herlyn M, Benes C, Gutkind JS, Flaherty K, Ruppin E. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.. [DOI: 10.1101/284240] [Reference Citation Analysis]
217 Stanicka J, Rieger L, O’shea S, Cox O, Coleman M, O’flanagan C, Addario B, Mccabe N, Kennedy R, O’connor R. FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion. Oncogene 2018;37:3131-50. [DOI: 10.1038/s41388-017-0113-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
218 Baker LA, Krisp C, Roden D, Holliday H, Wu SZ, Junankar S, Serandour AA, Mohammed H, Nair R, Chan C, Yang J, Foreman N, Fitzpatrick B, Sankaranarayanan G, Law AM, Ormandy C, Naylor MJ, Mcfarland A, Simpson PT, Lakhani S, O’toole S, Selinger C, Anderson L, Samimi G, Hacker NF, Kaplan W, Carroll JS, Molloy M, Swarbrick A. A novel role for the HLH protein Inhibitor of Differentiation 4 (ID4) in the DNA damage response in basal-like breast cancer.. [DOI: 10.1101/281196] [Reference Citation Analysis]
219 Patel N, Weekes D, Drosopoulos K, Gazinska P, Noel E, Rashid M, Mirza H, Quist J, Brasó-Maristany F, Mathew S, Ferro R, Pereira AM, Prince C, Noor F, Francesch-Domenech E, Marlow R, de Rinaldis E, Grigoriadis A, Linardopoulos S, Marra P, Tutt ANJ. Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. Nat Commun 2018;9:1044. [PMID: 29535384 DOI: 10.1038/s41467-018-03283-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
220 Gwynne WD, Hallett RM, Girgis-Gabardo A, Bojovic B, Dvorkin-Gheva A, Aarts C, Dias K, Bane A, Hassell JA. Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts. Oncotarget 2017;8:32101-16. [PMID: 28404880 DOI: 10.18632/oncotarget.16646] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
221 Weber L, Maßberg D, Becker C, Altmüller J, Ubrig B, Bonatz G, Wölk G, Philippou S, Tannapfel A, Hatt H, Gisselmann G. Olfactory Receptors as Biomarkers in Human Breast Carcinoma Tissues. Front Oncol 2018;8:33. [PMID: 29497600 DOI: 10.3389/fonc.2018.00033] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
222 Amornwachirabodee K, Tantimekin N, Pan-In P, Palaga T, Pienpinijtham P, Pipattanaboon C, Sukmanee T, Ritprajak P, Charoenpat P, Pitaksajjakul P, Ramasoota P, Wanichwecharungruang S. Oxidized Carbon Black: Preparation, Characterization and Application in Antibody Delivery across Cell Membrane. Sci Rep 2018;8:2489. [PMID: 29410523 DOI: 10.1038/s41598-018-20650-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
223 Saatci Ö, Borgoni S, Akbulut Ö, Durmuş S, Raza U, Eyüpoğlu E, Alkan C, Akyol A, Kütük Ö, Wiemann S, Şahin Ö. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Oncogene 2018;37:2251-69. [PMID: 29391599 DOI: 10.1038/s41388-017-0108-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
224 Urbanucci A, Mills IG. Bromodomain-containing proteins in prostate cancer. Molecular and Cellular Endocrinology 2018;462:31-40. [DOI: 10.1016/j.mce.2017.06.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
225 Wadi L, Meyer M, Weiser J, Stein LD, Reimand J. Impact of outdated gene annotations on pathway enrichment analysis. Nat Methods 2016;13:705-6. [PMID: 27575621 DOI: 10.1038/nmeth.3963] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 24.5] [Reference Citation Analysis]
226 Sahai V, Redig AJ, Collier KA, Eckerdt FD, Munshi HG. Targeting BET bromodomain proteins in solid tumors. Oncotarget 2016;7:53997-4009. [PMID: 27283767 DOI: 10.18632/oncotarget.9804] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 16.3] [Reference Citation Analysis]
227 Thu KL, Silvester J, Elliott MJ, Ba-Alawi W, Duncan MH, Elia AC, Mer AS, Smirnov P, Safikhani Z, Haibe-Kains B, Mak TW, Cescon DW. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. Proc Natl Acad Sci U S A 2018;115:E1570-7. [PMID: 29378962 DOI: 10.1073/pnas.1719577115] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
228 Hallett RM, Girgis-Gabardo A, Gwynne WD, Giacomelli AO, Bisson JN, Jensen JE, Dvorkin-Gheva A, Hassell JA. Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer. Oncotarget 2016;7:53137-52. [PMID: 27447971 DOI: 10.18632/oncotarget.10614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
229 Carcioppolo N, Christy KR, Jensen JD, King AJ, Goonewardene J, Raftery D. Biomarker profiling for breast cancer detection: translational research to determine acceptance of a novel breast cancer screening technique. Health Syst (Basingstoke) 2019;8:44-51. [PMID: 31214353 DOI: 10.1080/20476965.2017.1414740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
230 Chen Y, Byrne JA. Tumor Protein D52 (TPD52). Encyclopedia of Signaling Molecules 2018. [DOI: 10.1007/978-3-319-67199-4_101930] [Reference Citation Analysis]
231 Shi K, Gao L, Wang B. Inferring Dysregulated Pathways of Driving Cancer Subtypes Through Multi-omics Integration. Bioinformatics Research and Applications 2018. [DOI: 10.1007/978-3-319-94968-0_9] [Reference Citation Analysis]
232 Gautam P, Jaiswal A, Aittokallio T, Al-ali H, Wennerberg K. Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets. SSRN Journal. [DOI: 10.2139/ssrn.3263637] [Reference Citation Analysis]
233 Kondratyev M, Pesic A, Sayad A, Ketela T, Stickle N, Beswick C, Shalev Z, Marastoni S, Samadian S, Bashkurov M, Boasquevisque P, Datti A, Pugh TJ, Virtanen C, Moffat J, Grénman RA, Koritzinsky M, Wouters BG. Identification of Acquired Notch3 Dependency in Metastatic Head and Neck Cancer. SSRN Journal. [DOI: 10.2139/ssrn.3293686] [Reference Citation Analysis]
234 Franco HL, Nagari A, Malladi VS, Li W, Xi Y, Richardson D, Allton KL, Tanaka K, Li J, Murakami S, Keyomarsi K, Bedford MT, Shi X, Li W, Barton MC, Dent SYR, Kraus WL. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res 2018;28:159-70. [PMID: 29273624 DOI: 10.1101/gr.226019.117] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 15.8] [Reference Citation Analysis]
235 Selfors LM, Stover DG, Harris IS, Brugge JS, Coloff JL. Identification of cancer genes that are independent of dominant proliferation and lineage programs. Proc Natl Acad Sci U S A 2017;114:E11276-84. [PMID: 29229826 DOI: 10.1073/pnas.1714877115] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
236 Hunter FW, Tsai P, Kakadia PM, Bohlander SK, Print CG, Wilson WR. Development of capability for genome-scale CRISPR-Cas9 knockout screens in New Zealand. Journal of the Royal Society of New Zealand 2017;48:245-61. [DOI: 10.1080/03036758.2017.1400984] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
237 Sahni JM, Keri RA. Targeting bromodomain and extraterminal proteins in breast cancer. Pharmacol Res 2018;129:156-76. [PMID: 29154989 DOI: 10.1016/j.phrs.2017.11.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
238 Naidoo K, Wai PT, Maguire SL, Daley F, Haider S, Kriplani D, Campbell J, Mirza H, Grigoriadis A, Tutt A, Moseley PM, Abdel-Fatah TMA, Chan SYT, Madhusudan S, Rhaka EA, Ellis IO, Lord CJ, Yuan Y, Green AR, Natrajan R. Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. Mol Cancer Ther 2018;17:306-15. [PMID: 29133620 DOI: 10.1158/1535-7163.MCT-17-0760] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
239 Sharifnia T, Hong AL, Painter CA, Boehm JS. Emerging Opportunities for Target Discovery in Rare Cancers. Cell Chem Biol 2017;24:1075-91. [PMID: 28938087 DOI: 10.1016/j.chembiol.2017.08.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
240 Safikhani Z, Smirnov P, Thu KL, Silvester J, El-Hachem N, Quevedo R, Lupien M, Mak TW, Cescon D, Haibe-Kains B. Gene isoforms as expression-based biomarkers predictive of drug response in vitro. Nat Commun 2017;8:1126. [PMID: 29066719 DOI: 10.1038/s41467-017-01153-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 7.2] [Reference Citation Analysis]
241 Ryan CJ, Kennedy S, Bajrami I, Matallanas D, Lord CJ. A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events. Cell Syst 2017;5:399-409.e5. [PMID: 29032073 DOI: 10.1016/j.cels.2017.09.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
242 Gönen M, Weir BA, Cowley GS, Vazquez F, Guan Y, Jaiswal A, Karasuyama M, Uzunangelov V, Wang T, Tsherniak A, Howell S, Marbach D, Hoff B, Norman TC, Airola A, Bivol A, Bunte K, Carlin D, Chopra S, Deran A, Ellrott K, Gopalacharyulu P, Graim K, Kaski S, Khan SA, Newton Y, Ng S, Pahikkala T, Paull E, Sokolov A, Tang H, Tang J, Wennerberg K, Xie Y, Zhan X, Zhu F, Aittokallio T, Mamitsuka H, Stuart JM, Boehm JS, Root DE, Xiao G, Stolovitzky G, Hahn WC, Margolin AA; Broad-DREAM Community. A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines. Cell Syst 2017;5:485-497.e3. [PMID: 28988802 DOI: 10.1016/j.cels.2017.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
243 Lapek JD Jr, Greninger P, Morris R, Amzallag A, Pruteanu-Malinici I, Benes CH, Haas W. Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities. Nat Biotechnol 2017;35:983-9. [PMID: 28892078 DOI: 10.1038/nbt.3955] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 21.2] [Reference Citation Analysis]
244 Chan S, Sridhar P, Kirchner R, Lock YJ, Herbert Z, Buonamici S, Smith P, Lieberman J, Petrocca F. Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Mol Cancer Ther 2017;16:2849-61. [PMID: 28878028 DOI: 10.1158/1535-7163.MCT-17-0461] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
245 Senft D, Leiserson MDM, Ruppin E, Ronai ZA. Precision Oncology: The Road Ahead. Trends Mol Med 2017;23:874-98. [PMID: 28887051 DOI: 10.1016/j.molmed.2017.08.003] [Cited by in Crossref: 94] [Cited by in F6Publishing: 98] [Article Influence: 18.8] [Reference Citation Analysis]
246 Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 2017;170:605-635. [PMID: 28802037 DOI: 10.1016/j.cell.2017.07.029] [Cited by in Crossref: 1105] [Cited by in F6Publishing: 1179] [Article Influence: 221.0] [Reference Citation Analysis]
247 Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med 2017;23:1046-54. [PMID: 28805821 DOI: 10.1038/nm.4372] [Cited by in Crossref: 104] [Cited by in F6Publishing: 110] [Article Influence: 20.8] [Reference Citation Analysis]
248 Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM, Meyers RM, Ali L, Goodale A, Lee Y, Jiang G, Hsiao J, Gerath WFJ, Howell S, Merkel E, Ghandi M, Garraway LA, Root DE, Golub TR, Boehm JS, Hahn WC. Defining a Cancer Dependency Map. Cell 2017;170:564-576.e16. [PMID: 28753430 DOI: 10.1016/j.cell.2017.06.010] [Cited by in Crossref: 1127] [Cited by in F6Publishing: 1170] [Article Influence: 225.4] [Reference Citation Analysis]
249 Wang L, Li X, Zhang L, Gao Q. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization. BMC Cancer 2017;17:513. [PMID: 28768489 DOI: 10.1186/s12885-017-3500-5] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 15.8] [Reference Citation Analysis]
250 Hao J, Yang Z, Wang L, Zhang Y, Shu Y, Jiang L, Hu Y, Lv W, Dong P, Liu Y. Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. Int J Oncol 2017;51:823-31. [PMID: 28766687 DOI: 10.3892/ijo.2017.4081] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
251 Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, Gill S, Harrington WF, Pantel S, Krill-Burger JM, Meyers RM, Ali L, Goodale A, Lee Y, Jiang G, Hsiao J, Gerath WFJ, Howell S, Merkel E, Ghandi M, Garraway LA, Root DE, Golub TR, Boehm JS, Hahn WC. Defining a Cancer Dependency Map. Cell 2017;170:564-576.e16. [PMID: 28753430 DOI: 10.1016/j.cell.2017.06.010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
252 Chu X, Guo X, Jiang Y, Yu H, Liu L, Shan W, Yang ZQ. Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers - initial evidence of an oncogenic role for CHD7. Mol Oncol 2017;11:1348-60. [PMID: 28649742 DOI: 10.1002/1878-0261.12104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
253 Zhang Y, Shen H, Withers HG, Yang N, Denson KE, Mussell AL, Truskinovsky A, Fan Q, Gelman IH, Frangou C, Zhang J. VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. Sci Rep 2017;7:6190. [PMID: 28733631 DOI: 10.1038/s41598-017-06227-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
254 Safikhani Z, Thu KL, Silvester J, Smirnov P, Lupien M, Mak TW, Cescon D, Haibe-kains B. Gene isoforms as expression-based biomarkers predictive of drug response in vitro.. [DOI: 10.1101/160937] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
255 Bridgett S, Campbell J, Lord CJ, Ryan CJ. CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer. Cell Systems 2017;5:82-86.e3. [DOI: 10.1016/j.cels.2017.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
256 Lecomte S, Demay F, Ferrière F, Pakdel F. Phytochemicals Targeting Estrogen Receptors: Beneficial Rather Than Adverse Effects? Int J Mol Sci 2017;18:E1381. [PMID: 28657580 DOI: 10.3390/ijms18071381] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 14.0] [Reference Citation Analysis]
257 Ryan CJ, Kennedy S, Bajrami I, Matallanas D, Lord CJ. A compendium of co-regulated protein complexes in breast cancer reveals collateral loss events.. [DOI: 10.1101/155333] [Reference Citation Analysis]
258 Sood AK, Geradts J, Young J. Prostate-derived Ets factor, an oncogenic driver in breast cancer. Tumour Biol 2017;39:1010428317691688. [PMID: 28468594 DOI: 10.1177/1010428317691688] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
259 Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA, Davies MA, Deng W, Gopal YN, Chen G, von Euw EM, Slamon D, Conklin D, Heymach JV, Gazdar AF, Minna JD, Myers JN, Lu Y, Mills GB, Liang H. Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell 2017;31:225-39. [PMID: 28196595 DOI: 10.1016/j.ccell.2017.01.005] [Cited by in Crossref: 161] [Cited by in F6Publishing: 165] [Article Influence: 32.2] [Reference Citation Analysis]
260 Jaiswal A, Peddinti G, Akimov Y, Wennerberg K, Kuznetsov S, Tang J, Aittokallio T. Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells. Genome Med 2017;9:51. [PMID: 28569207 DOI: 10.1186/s13073-017-0440-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
261 Zhong S, Li Z, Jiang T, Li X, Wang H. Immunofluorescence Imaging Strategy for Evaluation of the Accessibility of DNA 5-Hydroxymethylcytosine in Chromatins. Anal Chem 2017;89:5702-6. [DOI: 10.1021/acs.analchem.7b01428] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
262 Hart T, Koh C, Moffat J. Coessentiality and cofunctionality: a network approach to learning genetic vulnerabilities from cancer cell line fitness screens.. [DOI: 10.1101/134346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
263 Johannessen CM, Boehm JS. Progress towards precision functional genomics in cancer. Current Opinion in Systems Biology 2017;2:74-83. [DOI: 10.1016/j.coisb.2017.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
264 Lin A, Giuliano CJ, Sayles NM, Sheltzer JM. CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife 2017;6:e24179. [PMID: 28337968 DOI: 10.7554/eLife.24179] [Cited by in Crossref: 73] [Cited by in F6Publishing: 88] [Article Influence: 14.6] [Reference Citation Analysis]
265 Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, Sircoulomb F, Krzyzanowski P, Novak M, Doodnauth SA, Saiz FS, Cullis J, Al-awar R, Neel BG, Mcpherson J, Drapkin R, Ailles L, Mes-massons A, Rottapel R. Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports 2017;18:2343-58. [DOI: 10.1016/j.celrep.2017.02.028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
266 Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, Santos ND, Silvester J, Wei V, Garcia J, Kabeer F, Lai D, Soriano P, Banáth J, Chiu DS, Yap D, Le DD, Ye FB, Zhang A, Thu K, Soong J, Lin SC, Tsai AH, Osako T, Algara T, Saunders DN, Wong J, Xian J, Bally MB, Brenton JD, Brown GW, Shah SP, Cescon D, Mak TW, Caldas C, Stirling PC, Hieter P, Balasubramanian S, Aparicio S. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nat Commun 2017;8:14432. [PMID: 28211448 DOI: 10.1038/ncomms14432] [Cited by in Crossref: 277] [Cited by in F6Publishing: 292] [Article Influence: 55.4] [Reference Citation Analysis]
267 Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S. Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. Cancer Res 2017;77:2476-87. [PMID: 28209615 DOI: 10.1158/0008-5472.CAN-16-2622] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 25.2] [Reference Citation Analysis]
268 Wang X, Guda C. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets. Medicine (Baltimore) 2016;95:e4321. [PMID: 27472710 DOI: 10.1097/MD.0000000000004321] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
269 Paolella BR, Gibson WJ, Urbanski LM, Alberta JA, Zack TI, Bandopadhayay P, Nichols CA, Agarwalla PK, Brown MS, Lamothe R, Yu Y, Choi PS, Obeng EA, Heckl D, Wei G, Wang B, Tsherniak A, Vazquez F, Weir BA, Root DE, Cowley GS, Buhrlage SJ, Stiles CD, Ebert BL, Hahn WC, Reed R, Beroukhim R. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife 2017;6:e23268. [PMID: 28177281 DOI: 10.7554/eLife.23268] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 11.0] [Reference Citation Analysis]
270 Shu S, Polyak K. BET Bromodomain Proteins as Cancer Therapeutic Targets. Cold Spring Harb Symp Quant Biol 2017;81:123-9. [DOI: 10.1101/sqb.2016.81.030908] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
271 Scott DC, Rhee DY, Duda DM, Kelsall IR, Olszewski JL, Paulo JA, de Jong A, Ovaa H, Alpi AF, Harper JW, Schulman BA. Two Distinct Types of E3 Ligases Work in Unison to Regulate Substrate Ubiquitylation. Cell 2016;166:1198-1214.e24. [PMID: 27565346 DOI: 10.1016/j.cell.2016.07.027] [Cited by in Crossref: 118] [Cited by in F6Publishing: 121] [Article Influence: 19.7] [Reference Citation Analysis]
272 Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. Cancer Res 2017;77:566-78. [PMID: 27872098 DOI: 10.1158/0008-5472.CAN-16-1901] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
273 Zhang W, Ben-David M, Sidhu SS. Engineering cell signaling modulators from native protein-protein interactions. Curr Opin Struct Biol 2017;45:25-35. [PMID: 27866084 DOI: 10.1016/j.sbi.2016.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
274 Taniguchi Y. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci 2016;17:E1849. [PMID: 27827996 DOI: 10.3390/ijms17111849] [Cited by in Crossref: 162] [Cited by in F6Publishing: 171] [Article Influence: 27.0] [Reference Citation Analysis]
275 Bridgett S, Campbell J, Lord CJ, Ryan CJ. CancerGD: a resource for identifying and interpreting genetic dependencies in cancer.. [DOI: 10.1101/081992] [Reference Citation Analysis]
276 Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao Z. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer. Breast Cancer Res Treat 2016;160:457-74. [PMID: 27771839 DOI: 10.1007/s10549-016-4011-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
277 Sahni JM, Gayle SS, Bonk KL, Vite LC, Yori JL, Webb B, Ramos EK, Seachrist DD, Landis MD, Chang JC, Bradner JE, Keri RA. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. J Biol Chem 2016;291:23756-68. [PMID: 27650498 DOI: 10.1074/jbc.M116.738666] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
278 Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell 2016;167:260-274.e22. [PMID: 27641504 DOI: 10.1016/j.cell.2016.08.041] [Cited by in Crossref: 304] [Cited by in F6Publishing: 314] [Article Influence: 50.7] [Reference Citation Analysis]
279 Muthukaruppan A, Lasham A, Woad KJ, Black MA, Blenkiron C, Miller LD, Harris G, McCarthy N, Findlay MP, Shelling AN, Print CG. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. Clin Breast Cancer 2017;17:139-53. [PMID: 27756582 DOI: 10.1016/j.clbc.2016.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
280 Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res 2016;18:90. [PMID: 27608715 DOI: 10.1186/s13058-016-0753-x] [Cited by in Crossref: 316] [Cited by in F6Publishing: 327] [Article Influence: 52.7] [Reference Citation Analysis]
281 Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, Duncan JS. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 2016;16:1273-86. [PMID: 27452461 DOI: 10.1016/j.celrep.2016.06.091] [Cited by in Crossref: 134] [Cited by in F6Publishing: 109] [Article Influence: 22.3] [Reference Citation Analysis]
282 Chiang CM. Phospho-BRD4: transcription plasticity and drug targeting. Drug Discov Today Technol 2016;19:17-22. [PMID: 27769352 DOI: 10.1016/j.ddtec.2016.05.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
283 Shi X, Mihaylova VT, Kuruvilla L, Chen F, Viviano S, Baldassarre M, Sperandio D, Martinez R, Yue P, Bates JG, Breckenridge DG, Schlessinger J, Turk BE, Calderwood DA. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms. Proc Natl Acad Sci U S A 2016;113:E4558-66. [PMID: 27432991 DOI: 10.1073/pnas.1608319113] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
284 Wang X. New biomarkers and therapeutics can be discovered during COPD-lung cancer transition. Cell Biol Toxicol 2016;32:359-61. [PMID: 27405768 DOI: 10.1007/s10565-016-9350-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
285 Chung CY, Sun Z, Mullokandov G, Bosch A, Qadeer ZA, Cihan E, Rapp Z, Parsons R, Aguirre-Ghiso JA, Farias EF. Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. Cell Rep. 2016;16:472-486. [PMID: 27346354 DOI: 10.1016/j.celrep.2016.06.002] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 11.2] [Reference Citation Analysis]
286 Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi AM, Wang J, Chen X, Dong H, Siu K, Winkler JD, Crew AP, Crews CM, Coleman KG. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2016;113:7124-9. [PMID: 27274052 DOI: 10.1073/pnas.1521738113] [Cited by in Crossref: 451] [Cited by in F6Publishing: 468] [Article Influence: 75.2] [Reference Citation Analysis]
287 Baldassarre G, Belletti B. Molecular biology of breast tumors and prognosis. F1000Res 2016;5:F1000 Faculty Rev-711. [PMID: 27134741 DOI: 10.12688/f1000research.8158.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
288 Reimand J, Arak T, Adler P, Kolberg L, Reisberg S, Peterson H, Vilo J. g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res 2016;44:W83-9. [PMID: 27098042 DOI: 10.1093/nar/gkw199] [Cited by in Crossref: 930] [Cited by in F6Publishing: 937] [Article Influence: 155.0] [Reference Citation Analysis]
289 Wadi L, Meyer M, Weiser J, Stein LD, Reimand J. Impact of knowledge accumulation on pathway enrichment analysis.. [DOI: 10.1101/049288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
290 Zhao Y, Chen J, Freudenberg JM, Meng Q, Rajpal DK, Yang X. Network-Based Identification and Prioritization of Key Regulators of Coronary Artery Disease Loci. Arterioscler Thromb Vasc Biol 2016;36:928-41. [PMID: 26966275 DOI: 10.1161/ATVBAHA.115.306725] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 7.2] [Reference Citation Analysis]
291 Guo X, Dixon JE. The 26S proteasome: A cell cycle regulator regulated by cell cycle. Cell Cycle 2016;15:875-6. [PMID: 26940127 DOI: 10.1080/15384101.2016.1151728] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
292 Chen Y, Byrne JA. Tumor Protein D52 (TPD52). Encyclopedia of Signaling Molecules 2016. [DOI: 10.1007/978-1-4614-6438-9_101930-1] [Reference Citation Analysis]
293 Verma M, Badve S. Epigenetic Mechanism in Breast Cancer. Molecular Pathology of Breast Cancer 2016. [DOI: 10.1007/978-3-319-41761-5_21] [Reference Citation Analysis]
294 [DOI: 10.1101/751776] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
295 [DOI: 10.1101/099739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]